Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mafenide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 1.00 |
| ▸ | CA1 | P00915 | 13/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 10/20 | 0.95 |
| ▸ | CA9 | Q16790 | 10/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.95 |
| ▸ | CA4 | P22748 | 5/20 | 0.95 |
| ▸ | CA6 | P23280 | 5/20 | 0.95 |
| ▸ | CA5A | P35218 | 5/20 | 0.95 |
| ▸ | CA7 | P43166 | 5/20 | 0.95 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mafenide SCHEMBL425524 | 1.00 | CA2 (1.00) | CA2CA1MAPTCA12CA9 | |
| Mafenide SCHEMBL686407 | 0.98 | CA2 (0.95) | CA2CA1MAPTCA12CA9 | |
| Mafenide SCHEMBL9295695 | 0.98 | CA2 (1.00) | CA2CA1MAPTCA12CA9 | |
| Mafenide SCHEMBL41628 | 0.98 | CA2 (1.00) | CA2CA1MAPTCA12CA9 | |
| Mafenide SCHEMBL2934434 | 0.93 | CA2 (0.91) | CA2CA1MAPTCA12CA9 | |
| Mafenide SCHEMBL1072130 | 0.91 | CA2 (0.87) | CA2CA1MAPTCA12CA9 | |
| Mafenide SCHEMBL27294054 | 0.91 | CA2 (0.87) | CA2CA1MAPTCA12CA9 | |
| Mafenide SCHEMBL11664949 | 0.89 | CA2 (0.83) | CA2CA1MAPTCA12CA9 | |
| Mafenide SCHEMBL27599824 | 0.87 | KDM4E (0.82) | CA2CA1MAPTCA12CA9 | |
| Mafenide SCHEMBL41627 | 0.86 | SMN1; SMN2 (1.00) | CA2CA1MAPTCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019172-B1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10273263-B2 | Pro-drug forming compounds | EVESTRA, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170349624-A1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9745338-B2 | Pro-drug forming compounds | EVESTRA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-3019172-A1 | PRO-DRUG FORMING COMPOUNDS | Evestra, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006691-A1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349624-A1 | PRO-DRUG FORMING COMPOUNDS | SUCNR1, FURIN, PROKR2 | CA2 941/4885CA1 1075/4885MAPT 3071/4885 |
| US-10273263-B2 | Pro-drug forming compounds | SUCNR1, FURIN, OGFR | CA2 1019/4885CA1 1272/4885MAPT 3110/4885 |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | CA2 2088/4885CA1 4357/4885MAPT 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.